Ambu downgrades financial expectations

After trading closed on Tuesday, Ambu lowered its expectations for its financial year of 2020/21 due to delayed component deliveries in its Core business.

by marketwire, translated by catherine brett

Published: 06.10.21 at 08:17

Medtech company Ambu has downgraded its financial guidance for its accounting year of 2020/21 after sales and income for its Core business were affected by the challenging global shipping conditions.

Ambu announced in a stock exchange notification that it now expects total organic growth for the year of 16 percent, compared to a previous estimate of 17 percent.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.